Health Reform 2007: Impact on the Valley

Provides a summary of California's health reform debate, background information on recent legislative action, and an overview of the major healthcare proposals pending in the state

Flavor decomposition of the elastic nucleon electromagnetic form factors

The u- and d-quark contributions to the elastic nucleon electromagnetic form factors have been determined using experimental data on GEn, GMn, GpE, and GpM. Such a flavor separation of the form factors became possible up to 3.4 GeV2 with recent data on GEn from Hall A at JLab. At a negative four-momentum transfer squared Q2 above 1 GeV2, for both the u- and d-quark components, the ratio of the Pauli form factor to the Dirac form factor, F2/F1, was found to be almost constant, and for each of F2 and F1 individually, the d-quark portions of both form factors drop continuously with increasing Q2.Comment: 4 pages, 3 figure

A Review of Issues Pertaining to Transgenic Turfgrasses

Recombinant DNA technology is a rapidly growing field in plant and animal breeding. This technology involves the transfer of pieces of DNA, or genes, regardless of the organisms involved or how they are related. Transformation procedures in plants were first developed for important crop and model plant systems. Although turfgrass management and production is one of the fastest growing areas of agriculture, genetic transformation of turfgrasses lags behind that of many other important crop plants. Turfgrasses are becoming more important primarily because of their association with the ever-increasing urban population. The size of the turfgrass seed market is second only to that of hybrid seed corn (Lee, 1996). However, much less is known about the genetics and physiology of turfgrasses. Many are polyploid, perennial, and/or outcrossing. These characteristics make them more difficult to study than many other crop plants. Use of transgenic technology in turfgrasses will likely follow as interest and corporate motivations allow. Application of transgenic technology is virtually limitless. The past few years have seen a rapid increase in releases of transgenic plants. Between 1987 and 1997, 3330 permits and notifications were filed with the U.S. Dept. of Agriculture (USDA–APHIS, 1998) for release of genetically engineered organisms in the United States. Twenty-nine percent involved herbicide tolerance and 24% insect resistance. Compared with the major crop species, genetically engineered turfgrasses are uncommon. By Dec. 1998, 31 permits and notifications had been filed on creeping bentgrass (Agrostis stolonifera L.) and two notifications on Kentucky bluegrass (Poa pratensis L.) (USDA–APHIS, 1998). But as additional genes are identified and cloned, a myriad of traits will probably be introduced into the turfgrasses. The first applications of transformation in turfgrasses were the incorporation of glufosinate [N,N-bis (phosphomethyl)glycine] resistance into creeping bentgrass (Lee et al., 1996; Liu et al., 1998), allowing application of a very effective nonselective herbicide to control unwanted weeds or other turfgrasses. In the future, recombinant DNA technology may be used to introduce other traits, such as insect resistance, disease resistance, and improved environmental stress tolerance. Transformation technology may offer many economic and agronomic benefits that are difficult or impossible to achieve through traditional breeding techniques (Dale, 1993). Essential steps of recombinant DNA technology include identification of the gene of interest, its isolation (cloning), study of the gene’s function and regulation, and introduction of the gene and expression factors into cells (Marois et al., 1991). Finally, the traits must be evaluated in an agriculturally desirable genotype

Sensitivity of an image plate system in the XUV (60 eV < E < 900 eV)

Phosphor imaging plates (IPs) have been calibrated and proven useful for quantitative x-ray imaging in the 1 to over 1000 keV energy range. In this paper we report on calibration measurements made at XUV energies in the 60 to 900 eV energy range using beamline 6.3.2 at the Advanced Light Source at Lawrence Berkeley National Laboratory. We measured a sensitivity of ~25 plus or minus 15 counts/pJ over the stated energy range which is compatible with the sensitivity of Si photodiodes that are used for time-resolved measurements. Our measurements at 900 eV are consistent with the measurements made by Meadowcroft et al. at ~1 keV.Comment: 7 pages, 2 figure

Exact Casimir Interaction Between Semitransparent Spheres and Cylinders

A multiple scattering formulation is used to calculate the force, arising from fluctuating scalar fields, between distinct bodies described by $\delta$-function potentials, so-called semitransparent bodies. (In the limit of strong coupling, a semitransparent boundary becomes a Dirichlet one.) We obtain expressions for the Casimir energies between disjoint parallel semitransparent cylinders and between disjoint semitransparent spheres. In the limit of weak coupling, we derive power series expansions for the energy, which can be exactly summed, so that explicit, very simple, closed-form expressions are obtained in both cases. The proximity force theorem holds when the objects are almost touching, but is subject to large corrections as the bodies are moved further apart.Comment: 5 pages, 4 eps figures; expanded discussion of previous work and additional references added, minor typos correcte

Nunalleq, Stories from the Village of Our Ancestors:Co-designing a multivocal educational resource based on an archaeological excavation

This work was funded by the UK-based Arts and Humanities Research Council through grants (AH/K006029/1) and (AH/R014523/1), a University of Aberdeen IKEC Award with additional support for travel and subsistence from the University of Dundee, DJCAD Research Committee RS2 project funding. Thank you to the many people who contributed their support, knowledge, feedback, voices and faces throughout the project, this list includes members of the local community, colleagues, specialists, students, and volunteers. If we have missed out any names we apologize but know that your help was appreciated. Jimmy Anaver, John Anderson, Alice Bailey, Kieran Baxter, Pauline Beebe, Ellinor Berggren, Dawn Biddison, Joshua Branstetter, Brendan Body, Lise Bos, Michael Broderick, Sarah Brown, Crystal Carter, Joseph Carter, Lucy Carter, Sally Carter, Ben Charles, Mary Church, Willard Church, Daniele Clementi, Annie Cleveland, Emily Cleveland, Joshua Cleveland, Aron Crowell, Neil Curtis, Angie Demma, Annie Don, Julia Farley, Veronique Forbes, Patti Fredericks, Tricia Gillam, Sean Gleason, Sven Haakanson, Cheryl Heitman, Grace Hill, Diana Hunter, Joel Isaak, Warren Jones, Stephan Jones, Ana Jorge, Solveig Junglas, Melia Knecht, Rick Knecht, Erika Larsen, Paul Ledger, Jonathan Lim Soon, Amber Lincoln, Steve Luke, Francis Lukezic, Eva Malvich, Pauline Matthews, Roy Mark, Edouard Masson-MacLean, Julie Masson-MacLean, Mhairi Maxwell, Chuna Mcintyre, Drew Michael, Amanda Mina, Anna Mossolova, Carl Nicolai Jr, Chris Niskanen, Molly Odell, Tom Paxton, Lauren Phillips, Lucy Qin, Charlie Roberts, Chris Rowe, Rufus Rowe,Chris Rowland, John Rundall, Melissa Shaginoff, Monica Shah, Anna Sloan, Darryl Small Jr, John Smith, Mike Smith, Joey Sparaga, Hannah Strehlau, Dora Strunk, Larissa Strunk, Lonny Strunk, Larry Strunk, Robbie Strunk, Sandra Toloczko, Richard Vanderhoek, the Qanirtuuq Incorporated Board, the Quinhagak Dance Group and the staff at Kuinerrarmiut Elitnaurviat. We also extend our thanks to three anonymous reviewers for their valuable comments on our paper.Peer reviewedPublisher PD

The structure of quotients of the Onsager algebra by closed ideals

We study the Onsager algebra from the ideal theoretic point of view. A complete classification of closed ideals and the structure of quotient algebras are obtained. We also discuss the solvable algebra aspect of the Onsager algebra through the use of formal Lie algebras.Comment: 33 pages, Latex, small topos corrected-Journal versio

Laguerre-type derivatives: Dobinski relations and combinatorial identities

We consider properties of the operators D(r,M)=a^r(a^\dag a)^M (which we call generalized Laguerre-type derivatives), with r=1,2,..., M=0,1,..., where a and a^\dag are boson annihilation and creation operators respectively, satisfying [a,a^\dag]=1. We obtain explicit formulas for the normally ordered form of arbitrary Taylor-expandable functions of D(r,M) with the help of an operator relation which generalizes the Dobinski formula. Coherent state expectation values of certain operator functions of D(r,M) turn out to be generating functions of combinatorial numbers. In many cases the corresponding combinatorial structures can be explicitly identified.Comment: 14 pages, 1 figur

Probiotics for people with hepatic encephalopathy

Background Hepatic encephalopathy is a disorder of brain function as a result of liver failure or portosystemic shunt or both. Both hepatic encephalopathy (clinically overt) and minimal hepatic encephalopathy (not clinically overt) significantly impair patient’s quality of life and daily functioning, and represent a significant burden on healthcare resources. Probiotics are live micro‐organisms, which when administered in adequate amounts, may confer a health benefit on the host. Objectives To determine the beneficial and harmful effects of probiotics in any dosage, compared with placebo or no intervention, or with any other treatment for people with any grade of acute or chronic hepatic encephalopathy. This review did not consider the primary prophylaxis of hepatic encephalopathy. Search methods We searched The Cochrane Hepato‐Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, conference proceedings, reference lists of included trials, and the World Health Organization International Clinical Trials Registry Platform until June 2016. Selection criteria We included randomised clinical trials that compared probiotics in any dosage with placebo or no intervention, or with any other treatment in people with hepatic encephalopathy. Data collection and analysis We used standard methodological procedures expected by The Cochrane Collaboration. We conducted random‐effects model meta‐analysis due to obvious heterogeneity of participants and interventions. We defined a P value of 0.05 or less as significant. We expressed dichotomous outcomes as risk ratio (RR) and continuous outcomes as mean difference (MD) with 95% confidence intervals (CI). Main results We included 21 trials with 1420 participants, of these, 14 were new trials. Fourteen trials compared a probiotic with placebo or no treatment, and seven trials compared a probiotic with lactulose. The trials used a variety of probiotics; the most commonly used group of probiotic was VSL#3, a proprietary name for a group of eight probiotics. Duration of administration ranged from 10 days to 180 days. Eight trials declared their funding source, of which six were independently funded and two were industry funded. The remaining 13 trials did not disclose their funding source. We classified 19 of the 21 trials at high risk of bias. We found no effect on all‐cause mortality when probiotics were compared with placebo or no treatment (7 trials; 404 participants; RR 0.58, 95% CI 0.23 to 1.44; low‐quality evidence). No‐recovery (as measured by incomplete resolution of symptoms) was lower for participants treated with probiotic (10 trials; 574 participants; RR 0.67, 95% CI 0.56 to 0.79; moderate‐quality evidence). Adverse events were lower for participants treated with probiotic than with no intervention when considering the development of overt hepatic encephalopathy (10 trials; 585 participants; RR 0.29, 95% CI 0.16 to 0.51; low‐quality evidence), but effects on hospitalisation and change of/or withdrawal from treatment were uncertain (hospitalisation: 3 trials, 163 participants; RR 0.67, 95% CI 0.11 to 4.00; very low‐quality evidence; change of/or withdrawal from treatment: 9 trials, 551 participants; RR 0.70, 95% CI 0.46 to 1.07; very low‐quality evidence). Probiotics may slightly improve quality of life compared with no intervention (3 trials; 115 participants; results not meta‐analysed; low‐quality evidence). Plasma ammonia concentration was lower for participants treated with probiotic (10 trials; 705 participants; MD ‐8.29 μmol/L, 95% CI ‐13.17 to ‐3.41; low‐quality evidence). There were no reports of septicaemia attributable to probiotic in any trial. When probiotics were compared with lactulose, the effects on all‐cause mortality were uncertain (2 trials; 200 participants; RR 5.00, 95% CI 0.25 to 102.00; very low‐quality evidence); lack of recovery (7 trials; 430 participants; RR 1.01, 95% CI 0.85 to 1.21; very low‐quality evidence); adverse events considering the development of overt hepatic encephalopathy (6 trials; 420 participants; RR 1.17, 95% CI 0.63 to 2.17; very low‐quality evidence); hospitalisation (1 trial; 80 participants; RR 0.33, 95% CI 0.04 to 3.07; very low‐quality evidence); intolerance leading to discontinuation (3 trials; 220 participants; RR 0.35, 95% CI 0.08 to 1.43; very low‐quality evidence); change of/or withdrawal from treatment (7 trials; 490 participants; RR 1.27, 95% CI 0.88 to 1.82; very low‐quality evidence); quality of life (results not meta‐analysed; 1 trial; 69 participants); and plasma ammonia concentration overall (6 trials; 325 participants; MD ‐2.93 μmol/L, 95% CI ‐9.36 to 3.50; very low‐quality evidence). There were no reports of septicaemia attributable to probiotic in any trial. Authors' conclusions The majority of included trials suffered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’). Accordingly, we consider the evidence to be of low quality. Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but probiotics may lead to little or no difference in mortality. Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available evidence is very low. High‐quality randomised clinical trials with standardised outcome collection and data reporting are needed to further clarify the true efficacy of probiotics